Notable life science industry activity for this coverage week: FDA approvals, clinical trial milestones, funding rounds, grants, and deals. Pulled from public industry data, not personalized to any one company or account.
If you work in clinical trial operations, patient recruitment, or the manufacturing side of drug development, this week points to a steady drumbeat of large late-stage studies all moving forward at once. We're not seeing a single breakthrough announcement or a funding event that reshapes the landscape. Instead, what caught our eye is the sheer scale and breadth of Phase 3 trials that are actively recruiting right now, all of them big enough to matter for the infrastructure that runs them.
The National Cancer Institute is recruiting across 1,150 clinical sites for a Phase 3 trial testing immunotherapy added to standard chemotherapy in non-small cell lung cancer, a common and serious form of the disease. Janssen is running a Phase 3 study comparing milvexian, a newer anticoagulant drug, to apixaban in atrial fibrillation patients at 1,052 sites. Novartis is recruiting for a Phase 3 study of inclisiran, a drug aimed at lowering cholesterol to prevent heart attacks and strokes, across 986 sites. Merck is conducting a long-term extension study of pembrolizumab, an immunotherapy, in solid tumors and blood cancers at 781 sites. Roche is comparing giredestrant to fulvestrant plus a CDK4/6 inhibitor, drugs that work together to slow hormone-driven breast cancer, at 352 sites. Seagen, owned by Pfizer, is testing SGN-B6A against docetaxel in previously treated lung cancer at 331 sites.
Trials of this scale tend to drive consistent demand for the companies that recruit patients, staff clinical sites, monitor data, and handle the specialized manufacturing that these therapies require. The thread here isn't that any single study is unusual. It's that they're all active at the same time, and collectively they represent thousands of sites and months of sustained operations work. We only see what we happen to pick up, so treat this as a few signals, not the whole board. Still, if your business depends on trial volume or manufacturing capacity, this lean is worth noticing.